XBiotech Inc. (NASDAQ:XBIT) has completed enrollment for a Phase I clinical trial for Hutrukin, a novel therapy aimed at reducing brain injury after stroke. The primary objective of the study is to evaluate the safety and pharmacokinetics of Hutrukin in healthy volunteers. Hutrukin is being developed to reduce brain injury following ischemic stroke, a leading cause of disability and death globally. The drug could potentially reduce the inflammatory injuries associated with reperfusion, a phenomenon that occurs during emergency stroke treatment.